Related Experiment Video
Updated: Jun 13, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Familial Hypercholesterolemia Combined With Sitosterolemia
Jia Sun1, Xiaofei Han2, Yuqiu He1
1Nanjing Medical University, Nanjing, Jiangsu Province, P.R. China.
Insights
This study reports the first case of co-occurring Familial Hypercholesterolemia (FH) and sitosterolemia, rare inherited lipid disorders. Targeted combination therapy successfully reduced lipids in this unique patient.
Area of Science:
- Genetics
- Metabolic Disorders
- Cardiovascular Health
Background:
- Hyperlipidemia encompasses diverse genetic and acquired conditions, with severe cases leading to vascular complications.
- Familial Hypercholesterolemia (FH) and sitosterolemia are distinct inherited lipid disorders.
- The simultaneous occurrence of FH and sitosterolemia has not been previously documented.
Background:
Hyperlipidemia is a heterogeneous disorder with genetic and acquired causes, and severe forms may cause vascular calcification and stenosis. Familial hypercholesterolemia (FH) and sitosterolemia are distinct inherited lipid diseases, yet their co-occurrence has not been previously reported.
Case Summary:
A patient with combined FH and sitosterolemia was identified via genetic testing. Single hypolipidemic therapies failed, whereas combined treatment targeting both disorders achieved significant lipid reduction.
Discussion:
This is to our knowledge the first reported case of concurrent FH and sitosterolemia, expanding the spectrum of inherited hyperlipidemia and highlighting the value of targeted therapy for dual lipid metabolic disorders.
Take-Home Message:
Genetic testing is indispensable for patients with refractory hyperlipidemia to guide precise combined hypolipidemic treatment.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipid Catabolism
Pharmacogenomics: Identification of New Drug Targets
Cholecystitis
Lipid Digestion
